{"title":"卡培他滨诱导高甘油三酯血症:一个未被报道的潜在严重副作用","authors":"S. Tabchi, K. Joseph","doi":"10.14312/2052-4994.2014-11","DOIUrl":null,"url":null,"abstract":"A 57 year-old-woman, with no previous history of dyslipedemia, developed severe hypertriglyceridemia while being treated with capecitabine for metastatic breast cancer. Capecitabine was not discontinued and serum triglyceride levels were normalized after 4 weeks of treatment with fenofibrate. Capecitabine induced hypertriglyceridemia, as a rare drugrelated side effect, seems to be often overlooked by clinicians.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"5 1","pages":"82-83"},"PeriodicalIF":0.0000,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Capecitabine induced hypertriglyceridaemia: An underreported and potentially severe side effect\",\"authors\":\"S. Tabchi, K. Joseph\",\"doi\":\"10.14312/2052-4994.2014-11\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A 57 year-old-woman, with no previous history of dyslipedemia, developed severe hypertriglyceridemia while being treated with capecitabine for metastatic breast cancer. Capecitabine was not discontinued and serum triglyceride levels were normalized after 4 weeks of treatment with fenofibrate. Capecitabine induced hypertriglyceridemia, as a rare drugrelated side effect, seems to be often overlooked by clinicians.\",\"PeriodicalId\":90205,\"journal\":{\"name\":\"Journal of cancer research & therapy\",\"volume\":\"5 1\",\"pages\":\"82-83\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer research & therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14312/2052-4994.2014-11\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research & therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14312/2052-4994.2014-11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Capecitabine induced hypertriglyceridaemia: An underreported and potentially severe side effect
A 57 year-old-woman, with no previous history of dyslipedemia, developed severe hypertriglyceridemia while being treated with capecitabine for metastatic breast cancer. Capecitabine was not discontinued and serum triglyceride levels were normalized after 4 weeks of treatment with fenofibrate. Capecitabine induced hypertriglyceridemia, as a rare drugrelated side effect, seems to be often overlooked by clinicians.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
